🇺🇸 FDA
Pipeline program

Esketamine, Sulfentanil or/and Remifentanil

ZGuo20200826

Unknown small_molecule active

Quick answer

Esketamine, Sulfentanil or/and Remifentanil for Opioid Analgesic Adverse Reaction is a Unknown program (small_molecule) at Second Affiliated Hospital of Soochow University with 1 ClinicalTrials.gov record(s).

Program details

Company
Second Affiliated Hospital of Soochow University
Indication
Opioid Analgesic Adverse Reaction
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials